Eton Pharmaceuticals Quarterly Balance Sheet
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eton Pharmaceuticals financial position
As of Jun 30, 2026, Eton Pharmaceuticals reported total assets of $115.8 million, up 13.9% from a year earlier against total liabilities of $69.2 million. Shareholders' equity stood at $46.6 million, or 40.2% of assets. The company held $26.8 million in cash and equivalents against $27.9 million of debt, a net debt position of $1.1 million.
The current ratio (current assets divided by current liabilities) was 1.52, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.60.
Summary generated from market data by MetaCap's automated system. Methodology
Eton Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 26.84M | 19.66M | 25.94M | 37.12M | 25.38M | 17.42M | 14.94M | 20.26M | 17.69M | 16.66M | 21.39M | 22.07M |
| Receivables | 24.89M | 13.41M | 11.76M | 13.08M | 14.45M | 16.40M | 5.36M | 5.59M | 4.87M | 4.24M | 3.41M | 3.50M |
| Inventory | 10.14M | 14.47M | 15.42M | 16.86M | 23.79M | 13.62M | 15.23M | 1.94M | 2.07M | 2.32M | 911.00K | 1.05M |
| Total Current Assets | 68.60M | 53.24M | 60.58M | 72.00M | 68.44M | 49.96M | 41.02M | 29.75M | 25.43M | 24.26M | 26.84M | 27.16M |
| Property, Plant & Equipment | 352.00K | 372.00K | 326.00K | 294.00K | 18.00K | 22.00K | 34.00K | 33.00K | 45.00K | 57.00K | 58.00K | 38.00K |
| Intangible Assets | 45.68M | 43.74M | 30.88M | 31.88M | 32.88M | 33.88M | 34.88M | 5.85M | 6.12M | 6.39M | 4.74M | 4.21M |
| Total Assets | 115.81M | 97.71M | 92.11M | 104.51M | 101.68M | 84.03M | 76.12M | 35.84M | 31.82M | 30.79M | 31.74M | 31.53M |
| Accounts Payable | 14.40M | 13.48M | 10.98M | 14.26M | 12.14M | 4.87M | 4.17M | 2.68M | 2.13M | 2.26M | 1.85M | 1.71M |
| Short-Term Debt | 8.82M | 11.81M | 8.79M | 2.78M | 2.77M | — | 0 | 4.13M | 4.66M | 5.02M | 5.38M | 1.54M |
| Total Current Liabilities | 45.12M | 44.18M | 38.49M | 44.18M | 38.60M | 25.35M | 19.95M | 19.73M | 18.22M | 15.30M | 16.24M | 10.39M |
| Long-Term Debt | 19.08M | 18.94M | 21.77M | 27.59M | 27.41M | 29.99M | 29.81M | — | — | — | 0 | 4.20M |
| Total Liabilities | 69.22M | 67.09M | 65.96M | 81.38M | 77.72M | 59.58M | 51.70M | 19.86M | 18.36M | 15.30M | 16.26M | 14.63M |
| Shareholders' Equity | 46.59M | 30.61M | 26.15M | 23.13M | 23.96M | 24.45M | 24.43M | 15.98M | 13.46M | 15.49M | 15.48M | 16.89M |
| Retained Earnings | -99.36M | -110.94M | -112.49M | -113.98M | -112.05M | -109.47M | -107.89M | -107.30M | -107.92M | -104.88M | -104.07M | -101.81M |
| Total Debt | 27.90M | 30.75M | 30.56M | 30.37M | 30.18M | 29.99M | 29.81M | 4.13M | 4.66M | 5.02M | 5.38M | 5.74M |
| Net Cash (Debt) | -1.06M | -11.09M | -4.62M | 6.75M | -4.80M | -12.57M | -14.88M | 16.14M | 13.04M | 11.63M | 16.01M | 16.33M |
| Shares Outstanding | 28.29M | 27.36M | 27.05M | 26.82M | 26.82M | 26.82M | 26.71M | 25.84M | 25.75M | 25.69M | 25.69M | 25.66M |
This table shows 12 quarterly periods of Eton Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow ETON's reporting calendar. What is a balance sheet?